OBJECTIVES: Cardiac surgery for prosthetic valve endocarditis (PVE) represents one of the highest risk surgeries with in-hospital mortality of 20%. Given the complex nature of the operation, the operative outcome is likely strongly susceptible to the surgeon's experience and centre case volume, as measurements often are not apparent in large observational studies. We sought to evaluate operative outcomes and mid-term survival of patients with PVE compared with those of native valve endocarditis (NVE) at a tertiary care hospital.
Comparable perioperative outcomes and mid-term survival in prosthetic valve endocarditis and native valve endocarditis 
INTRODUCTION
Prosthetic valve endocarditis (PVE) represents approximately 20% of all endocarditis and portends poor clinical outcomes [1, 2] . Despite significant changes in the standards of prophylaxis and therapy over the last 2 decades, its incidence is increasing in the USA [3] . In a large international observational study, approximately 50% of patients with PVE underwent surgery during the admission during which the diagnosis was made, and survival advantage associated with surgery was observed in patients with strong indications for surgical intervention [4] . Despite the apparent benefit, cardiac surgery for PVE represents one of the highest risk surgeries with in-hospital mortality of 20% [5] . With the high acuity of comorbid patients and complex nature of the surgical removal of the infected prosthesis and reconstruction of paravalvular structures, surgical treatment of this condition presents a formidable challenge to surgeons. Given the complex nature of the operation, the operative outcome is likely strongly susceptible to surgeon experience and centre case volume [6] , as measurements are often not apparent in large observational studies.
In this study, we sought to evaluate operative outcomes and mid-term survival of patients with PVE who underwent operative intervention at a tertiary care hospital. Comparisons with native valve endocarditis (NVE) are made as a reference point.
METHODS

Patient population
We conducted a single-institutional retrospective review of 188 consecutive patients (146 NVE and 42 PVE) undergoing cardiac surgery for endocarditis between 2011 and 2016 at Yale-New Haven Hospital, a tertiary care hospital in the USA. Endocarditis was defined according to the Centers for Disease Control and Prevention (CDC) surveillance definitions [7] . The CDC definition is adopted by the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) and closely resembles the Duke Criteria for infective endocarditis (IE) [8] . PVE was defined as patients with endocarditis requiring explantation of a prosthetic valve. The STS definitions for active and treated IE were used: endocarditis was considered active if the patient was receiving treatment for endocarditis. The disease was considered treated if antibiotic therapy (other than prophylactic medication) had been completed at the time of surgery. The Yale Institutional Review Board approved the study, and individual patient consent was waived.
Surgical indications and operative approaches
In general, surgical indications for active endocarditis are guideline-directed, including patients with large vegetations, active distal embolic phenomena and severe valvular dysfunctions, and haemodynamic compromise due to valvular dysfunction. Nonactive endocarditis patients were operated on within the realm of valve disease guidelines, although sometimes patients from outside facilities were found to have persistent or enlarging vegetations after completing antibiotic therapy. Outside of case-by-case variations, general surgical principles at the Yale-New Haven Hospital for patients with IE are based on the radical debridement of all infected tissue and infected prosthesis. If the valvular structure is assessed to be intact without the extension of infection, vegetations are debrided, and attempts are made to preserve the native valvular apparatus. The removal of infected material is followed by generous irrigation. Allografts are used almost exclusively for aortic root reconstruction in cases with annulus destruction and periannular invasion. When the annular structure requires reconstruction with additional material, autologous pericardium is preferred. The use of non-biological material is kept to a minimum.
Collected data and outcomes
Baseline demographic data (Table 1 ) and operative and postoperative data (Table 2) were collected. The STS data definitions (versions 2.81 and 2.73) were used. Preoperative stroke was defined as those occurring within 30 days of surgery. In addition, operative variables were collected to delineate the presence of annular abscess, operations involving root replacement or remodelling and abscess debridement. The evaluated outcomes are perioperative mortality, perioperative composite adverse events [operative mortality and composite events (death, stroke, prolonged intubation, renal failure, and sepsis)] and mid-term survival. Following definitions were used for the adverse events: postoperative prolonged intubation as mechanical ventilation >24 h, postoperative renal failure as either new dialysis requirement in the postoperative period, increase in serum creatinine level 3 times greater than baseline or postoperative serum creatinine level > _ 4 mg/dl, sepsis as the presence of systemic inflammatory response syndrome and suspected or proven infection and stroke as neurological deficit of abrupt onset caused by a disturbance in blood supply to the brain that did not resolve within 24 h. Perioperative data were collected up to the postoperative day 30 or up to the time of hospital discharge, whichever was longer. Of note, the required course of intravenous (IV) antibiotics therapy is often completed at lower-acuity institutions following the discharge from the index hospitalization. Postdischarge follow-up was ascertained via a combination of institutional electronic chart review and linking the institutional database to Connecticut State Department of Public Health death records, which captures all mortality that occurred in the Connecticut state residents. The final date of follow-up was 1 November 2017.
Statistical analysis
Differences in the patient characteristics between the NVE and PVE cohorts were compared using the 2-tailed t-test for continuous variables, the v 2 test for categorical variables or the Fisher's exact test for categorical variables with cell count < _ 5. Continuous variables including cross-clamp time are expressed as mean with standard deviation unless otherwise specified and in the Tables 1,  2 , and 3, categorical variables are expressed as percentages. Endocarditis risk score, a point-based risk score system derived from the national STS database, was used to quantify preoperative risks [9] . A logistic regression model for the perioperative composite adverse events [operative mortality and composite events (death, stroke, prolonged intubation, renal failure and sepsis)] was developed using the following input variables: PVE status, age, race, BMI, history of diabetes, dialysis-dependent renal failure, chronic lung disease, liver disease, history of stroke, pneumonia, IV drug abuse, congestive heart failure, active endocarditis, peripheral vascular disease, non-elective case status and number of valves operated on. Backward elimination was performed using PVE status as a forced input, and the final variables retained in the model are reported in Table 3 . The Kaplan-Meier analysis was used to estimate the mid-term survival, and the log-rank test was used to assess the difference between PVE and NVE. The Cox proportional hazard model was fitted to the entire dataset to assess the adjusted risk associated with mid-term survival, using the same input variables used for the logistic regression model above. The proportional hazards assumption in the Cox model for covariates, including PVE and NVE statuses, was tested. This was done by examining the log-log Kaplan-Meier curves of the covariates, and variables violating the assumption were stratified in the final Cox model.
A P-value <0.05 was used to define statistically significant differences and correlations. All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline patient characteristics and variables specific to endocarditis are outlined in Table 1 . At baseline, patient comorbidities were similar between the PVE and NVE groups. A larger proportion of patients in the PVE group had a history of undergoing coronary artery bypass graft and valve surgery: P = 0.017 and P <0.001, respectively. Endocarditis risk score, a score system derived from the national STS database to predict perioperative mortality [9] , was significantly higher in the PVE cohort when compared with the NVE cohort: 37.3 points vs 28.3 points, P <0.001. A score of 37 points was correlated with an approximately 11% risk of perioperative mortality and a score of 28 points was correlated with an approximately 8% risk of perioperative mortality based on the original derivation [9] . History of IV drug use was not significantly different between PVE and NVE: 9 (22%) vs 46 (32%), respectively.
Operative variables are outlined in Table 2 . None of the operative variables were significantly different between PVE and NVE, with the exception of a higher incidence of root replacement in PVE when compared with NVE (4% vs 14%, P =0.032), and prior sternotomy rate, which was present in 100% of the PVE cohort. Urgent operation was performed in 83% and 71% of patients with PVE and NVE, respectively. Multivalve surgeries accounted for 67% and 57% of the PVE and NVE cohorts, respectively (P = 0.49). When compared with the NVE cohort, mean aortic a IDDM and NIDDM percentages are calculated with number of patients with diabetes as the denominator. Similarly, the percentages of ischaemic and haemorrhagic stroke are calculated with stroke as the denominator. CABG: coronary artery bypass graft; CHF: congestive heart failure; EF: ejection fraction; IDDM: insulin-dependent diabetes mellitus; IV: intravenous; MI: myocardial infarction; MR: mitral regurgitation; NIDDM: non-insulin-dependent diabetes mellitus; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; SD: standard deviation.
cross-clamp time was longer in the PVE cohort with a trend toward significance: 108 min vs 96 min, respectively (P = 0.090).
Operative outcomes are outlined in Table 3 . In this series, mortality was 4.1% for NVE and 0% for PVE (P = 0.34). Composite events (operative death, dialysis, renal failure, pneumonia, prolonged ventilator requirement, stroke and sepsis) occurred in 30.6% and 38.1% of NVE and PVE, respectively (P = 0.45). None of the evaluated outcomes showed statistically significant difference between the NVE and PVE cohorts upon univariable comparisons. Multivariable logistic regression for operative mortality did not converge due to lack of event in the PVE cohort. The multivariable logistic regression for composite events (Table 4) showed that PVE was not associated with increased risk of adverse events [odds ratio (OR) 1.37, 95% confidence interval (CI) 0.56-3.36; P = 0.49]. Active endocarditis status compared with treated status was associated with increased risk of adverse event: OR 3.54, 95% CI 1.05-11.91; P = 0.041. With regard to post-discharge followup, 6-month follow-up was complete in 183 (97.3%) patients and 1-year follow-up was complete in 175 (93.1%) patients. Figure 1 represents the Kaplan-Meier analysis for unadjusted mid-term survival. There was no statistically significant difference in survival (P = 0.99). The Cox proportional hazard analysis for long-term mortality demonstrated that PVE was not associated with increased risk for hazard of death: hazard ratio 0.4, 95% CI 0.2-1.1; P = 0.085. Other predictors of mid-term mortality are outlined in Table 5 . History of lung disease and peripheral vascular disease were associated with an increased risk of long-term death.
DISCUSSION
Several salient findings arise from this retrospective analysis of consecutive endocarditis patients undergoing surgical treatment: (i) operative mortality was low in both the NVE and PVE cohorts, with no operative mortality occurring in the PVE cohort, (ii) multiple logistic regression in both the unmatched and matched cohorts showed that PVE was not associated with increased risk of operative mortality or composite adverse events when compared with NVE cases and (iii) mid-term survival, both adjusted and unadjusted, was comparable in the PVE cohort and the NVE cohort.
The surgical cohort in this study represents a selected patient population assessed to be fit for surgical intervention. Single-tertiary-institutional outcomes may differ from international observational cohorts. With no operative mortalities in our PVE cohort, our results compare favourably to the surgical cohort of the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) with a reported in-hospital mortality of 22% [4] or an Italian national registry with a reported in-hospital mortality of 19% [5] . Several risk factors identified in the ICE-PCS, including the presence of congestive heart failure and other chronic illnesses, were also present in our series at a comparable rate. In addition, the endocarditis risk score of 37 points with corresponding predicted operative mortality of approximately 11% argues that our PVE cohort consisted of comparably sick patients. A possible explanation for the low mortality rate may be the inclusion of non-active endocarditis population, which comprised 23% (43 of 188) of the cohort. Although the mortality in the series remains low even when non-active endocarditis patients are excluded, an other centres described a perioperative mortality rate of 13% when only active endocarditis was analysed [10] . Another possible element may be the relatively high volume of endocarditis cases treated at our centre, resulting in surgical expertise and a perioperative environment equipped to provide these patients with highly specialized care, although this effect was not explored in this study. In addition, the ICE-PCS cohort consisted of multicentre international recruitments, and surgical outcomes varied across a range of the propensity of undergoing surgical treatment [4] , a phenomenon that was likely minimized in our single-institutional setting with a relatively standardized propensity for operative management. Operative mortality as low as 6.5% has been reported in a single-centre series [11] . Importantly, the fraction of patients with a history of IV drug use may be relatively high when compared with what has been reported by other centres, and this likely owes to the current opioid endemic. Reports from another centre, which is in the geographic proximity to our centre, reported a similar rate of 26.1% in the most recent era [12] . Although the perioperative risk in patients with active IV drug use may be lower, risk-adjusted survival is not significantly different when compared with the cohort without IV drug use.
An important implication drawn from this study is in the context of perceived risk of operative management for IE. In a series of 1296 patients with left-sided IE in an international prospective registry for endocarditis, approximately one-quarter of patients meeting operative indications did not undergo surgery, with the most common reason for electing non-operative management being the perception of poor prognosis [13] . Endocarditis, whether NVE or PVE, is associated with high operative risks. The operative outcome is likely dependent on the treatment environment, with inverse associations between centre case volume and incidences of adverse event rates, as demonstrated in an array of complex surgeries [6, 14, 15] . This association has not been examined specifically in surgery for endocarditis and may provide further insight into ways to improve operative management of this complex disease entity. The importance of experienced operators and availability of a multidisciplinary team equipped to handle various complications are highlighted in the American Association for Thoracic Surgery consensus guideline [16] . Surprisingly, our analysis demonstrated comparable outcomes between the PVE and NVE cohorts. This was examined from multiple perspectives with utilization of the multivariable logistic regression for perioperative composite adverse events, the KaplanMeier analysis for unadjusted mid-term survival and the Cox proportional hazard model for adjusted mid-term survival, all of which demonstrated no statistically significant differences. Our PVE and NVE cohorts were well balanced in baseline characteristics, with the exception of the prior valve surgery history, which appeared to be the driver of significantly higher endocarditis risk score in the PVE cohort. Examination of intraoperative variables revealed that both cohorts underwent similar operations, with comparable frequencies of complex, double-valve and triple-valve operations and similar cross-clamp times. Extrapolated from the results of multiple models, the status of PVE alone may not confer significant increase in the risk of adverse events.
Reports on the direct comparison between PVE and NVE are sparse. A single-institutional series of surgically managed IE in Singapore including 179 patients with 7% PVE reported operative mortality of 6.3% and 90% survival at 1 year [17] . Although the incidence of surgically treated PVE in this series was low, PVE was not an independent predictor of hospital death in their series. 
Limitations
The findings of our study should be interpreted in the context of the following limitations. This study harbours limitations inherently associated with its retrospective nature. The cohort of PVE that did not undergo surgical management was not captured, and hence, the characterization of the surgical PVE cohort in comparison with the non-operative PVE cohort was not possible. This single-institutional series is limited in its generalizability. However, the strength of this study also lies in its single-institutional nature, whereby a standardized process was adopted in the care of these patients.
CONCLUSIONS
Surgical management of PVE can be performed with a low mortality rate. Mid-term survival, comparable with patients with NVE, can be achieved in patients with PVE. Although daunting, the diagnosis of PVE alone should not deter surgeons from pursuing surgical management in this complex patient population. As one of the highest risk and most technically challenging cardiac operations, we recommend that surgery for IE is best conducted at high-volume centres with experienced operators and multidisciplinary teams equipped with the relevant expertise.
